Exp Clin Endocrinol Diabetes 2009; 117(5): 220-222
DOI: 10.1055/s-0028-1119405
Article

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Insulin Injections in Type 2 Diabetes: A Meta-analysis

M. Monami 1 , C. Lamanna 1 , N. Marchionni 1 , E. Mannucci 1
  • 1Section of Geriatric Cardiology, Department of Cardiovascular Medicine, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
Weitere Informationen

Publikationsverlauf

received 28.08.2008 first decision 29.10.2008

accepted 17.12.2008

Publikationsdatum:
19. März 2009 (online)

Preview

Abstract

Background: Continuous Subcutaneous Insulin Infusion (CSII) improves HbA1c in type 1 diabetic patients unsatisfactorily controlled by Multiple Daily Injections (MDI). Few trials have explored CSII for basal-bolus therapy in type 2 diabetes.

Materials and Methods: Randomized Clinical Trials (RCTs) comparing CSII and MDI for at least 12 weeks in type 2 diabetic patients were retrieved, assessing between-group differences in HbA1c and insulin daily dose at endpoint, and incidence of hypoglycemia.

Results: A total of 4 RCTs was included in the analysis. CSII did not produce any significant improvement of HbA1c in comparison with MDI (Standardized difference in mean: 0.09(−0.08;0.26)%; p=0.31). No significant difference was observed in the rate of hypoglycemic episodes. CSII was associated with a nonsignificant trend toward the reduction of insulin doses used at the end of trial.

Conclusions: Available data do not justify the use of CSII for basal-bolus insulin therapy in type 2 diabetes.

References

Correspondence

E. MannucciMD 

Department of Cardiovascular Medicine

Section of Geriatric Cardiology

Azienda Ospedaliero-Universitaria Careggi

Via delle Oblate 4: 50141 Florence

Italy

Telefon: +39/055/794 95 98

Fax: +39/055/794 96 60

eMail: edoardo.mannucci@unifi.it

eMail: mmonami@libero.it